Engineered CXCL12 α locked dimer polypeptide
AssigneesThe Medical College of Wisconsin, Inc., The Rockefeller University
InventorsBrian F. Volkman, Christopher T. Veldkamp, Francis C. Peterson, Thomas Sakmar, Christoph H. Seibert
Life of this patent
Estimating the term…
Abstract
The present invention provides a novel CXCL12-α2 locked dimer polypeptide, pharmaceutical compositions thereof, and methods of using said dimer in the treatment of cancer, inflammatory disorders, autoimmune disease, and HIV/AIDS.
Claims13
A CXCL12-α2 locked dimer polypeptide, wherein the dimer comprises two monomers locked together.
An isolated CXCL12-α2 locked dimer polypeptide, wherein the dimer consists of two monomers locked together.
A method of treating a solid tumor in a subject comprising administering to the subject a therapeutically effective amount of a composition comprising a CXCL12-α2 locked dimer polypeptide.
A method of inhibiting angiogenesis in a subject by administering to the subject a therapeutically effective amount of a composition comprising a CXCL12-α2 locked dimer polypeptide.
A kit comprising a CXCL12-α2 locked dimer polypeptide wherein the dimer comprises monomers having the amino acid sequence as shown in SEQ ID NO:1, a pharmaceutically acceptable carrier or diluent, and instructional material.
Dependencies are inferred from the claim text.